ضبط کو آزما رہا ہوں میں
بے وفا سے نبھا رہا ہوں میں
لوگ کہنے لگے ہیں دیوانہ
ایسے اعزاز پا رہا ہوں میں
بخدا میرے بس کی بات نہیں
جتنے صدمے اٹھا رہا ہوں میں
میرے احباب کو مبارک ہو
چھوڑ کر شہر جا رہا ہوں میں
عشق کی آگ کیوں نہیں بجھتی
کب سے تائبؔ بجھا رہا ہوں میں
A family is the fundamental unit of society. Every society has the presence of a family. The start of a family's life is entirely dependent on matters of co. human relations. All such human relationships are entrenched in islamic sharia as a sacred bond of nikah, in which a husband and wife become a part of the world in the form of a family's collective result. Husband and wife are the most fundamental pillars of society, and their affection and companionship provides a source of stability for them and also a refuge for coming generations.A family consist of husband ,wife and their children . The family life is begins with marriage, after marriage every woman wants to have her own separate home where all the requirements of privacy are met. Islam has placed the entire responsibility of livelihood on men..But in our society there are two types of family system joint and separate family system. In Pakistan The joint family system is prevalent. The people of the subcontinent are not only adopting this system but they are also feel proud of it . In the present article the joint family system has facing many challenges. One of them is accommodation. In this article will focus on what is the basic concept of accommodation in joint family systems and its solution in Islami teachings. It is critical for the husband and wife to have a home where no one can interfere on their personal matters. This interference is very much in our society.Which husband and wife facing many problems. And due to this conditions, the relationship of husband and wife is also affected.
Key Words: Joint family system, Issues of Accommodation, Pakistani society, Islamic teachings.
Mesenchymal stromal cells (MSCs) represent a rare population of multipotent stem cells found in many adult tissues. In bone marrow MSCs support haematopoiesis by providing marrow stroma. MSCs have recently emerged as an exciting candidate for cellular therapy due to their hypoimmunogenic properties and ability to differentiate into different tissue types. With the intent of optimizing large-scale expansion of MSCs for clinical use, we compared different culturing conditions for their ability to support growth and proliferation of bone marrow MSCs (BM-MSCs). We evaluated cells cultured in Alpha Modified Eagle Medium (αMEM), Dulbecco’s modified Eagle medium (DMEM) in the presence of either 10% fetal bovine serum (10% FBS), 10% pooled human platelet lysate (10% pHPL) or commercial serum-free formulation (StemPRO® MSC SFM). We concluded that supplementing growth medium with pHPL resulted in superior cell yield than fetal bovine serum (FBS) and comparable to commercial serum-free formulation. Study II was a phase-I human clinical trial, establishing safety of autologous BM-MSC transplantation in nine spinal cord injury patients. For this ex vivo expanded MSCs were injected intrathecally after premedication. All of our patients tolerated the procedure well and no complication was observed during a median follow up of 644 days. Some of the patients with sub-acute disease reported subjective improvement in sensory and neurological functions. Lastly we carried out a phase-I/II trial of MSCs in allogeneic use as a treatment option in treating steroid-resistant graft versus host disease (GVHD). GVHD is a life threatening complication of allogeneic stem cell xii transplantation and only a fraction of patients are cured through steroids. Those who fail to respond to steroid have a very poor prognosis. The patients received third party BM MSCs as their bone marrow MSCs were failing to cope with the immunemediated tissue destruction by donor T cells. A total of 33 MSC infusions were given to 10 patients suffering from acute GVHD (n=3), chronic GVHD (n=5) and overlap syndrome (n=2). Eight out of ten patients are alive after a median follow up of 11 months with five having sustained CR. Three patients with partial response received further doses to sustain response. One of them died of lung infection while others are still alive. One out of the two non-responding patients died after 17 days of MSC therapy due to advanced liver GVHD while the other is having stable disease course. The overall and disease-free survival was 80% and 50% respectively. The patients developed no complication or toxicity related to MSC infusion. Luminex analysis revealed a modest drop after MSC infusion in pro-inflammatory cytokines like IFNγ, TNFα, IL-1β, IL-2, IL-4, IL-6, IL-17A and IL-17F, whereas serum IL-10 levels were slightly raised. Overall a total of 57 preparations of cultured stem cells were made which were transplanted via I.V. or I.T. route with no adverse event or serious complication to report. Therefore it is concluded that MSCs can be safely given in both autologous as well as allogeneic setting as cellular therapy in selected clinical situations. This initial data on safety and efficacy calls for taking these clinical trials into advanced phase with more detailed account of efficacy measures and addition of placebo groups.